1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS

S. Suciu; A.M.M. Eggermont; P. Lorigan; J. Kirkwood; S. Markovic; C. Garbe; D. Cameron; S. Kotapati; C. Konto; T. Chen; K. Wheatley; N. Ives; G. De Schaetzen; A. Efendi; M. Buyse

doi:10.1093/annonc/mdu344.5

1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS

S. Suciu, A.M.M. Eggermont, P. Lorigan, J. Kirkwood, S. Markovic, C. Garbe, D. Cameron, S. Kotapati, C. Konto, T. Chen, K. Wheatley, N. Ives, G. De Schaetzen, A. Efendi, M. Buyse

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	iv376-iv376
Journal	Annals of Oncology
Volume	25
Issue number	suppl_4
DOIs	https://doi.org/10.1093/annonc/mdu344.5
Publication status	Published - 3 Feb 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdu344.5

Cite this

Suciu, S., Eggermont, A. M. M., Lorigan, P., Kirkwood, J., Markovic, S., Garbe, C., Cameron, D., Kotapati, S., Konto, C., Chen, T., Wheatley, K., Ives, N., De Schaetzen, G., Efendi, A., & Buyse, M. (2017). 1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS. Annals of Oncology, 25(suppl_4), iv376-iv376. https://doi.org/10.1093/annonc/mdu344.5

@article{4aca434d9ca3470f90d7df2c5ad13635,

title = "1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS",

author = "S. Suciu and A.M.M. Eggermont and P. Lorigan and J. Kirkwood and S. Markovic and C. Garbe and D. Cameron and S. Kotapati and C. Konto and T. Chen and K. Wheatley and N. Ives and {De Schaetzen}, G. and A. Efendi and M. Buyse",

year = "2017",

month = feb,

day = "3",

doi = "10.1093/annonc/mdu344.5",

language = "English",

volume = "25",

pages = "iv376--iv376",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "suppl_4",

}

Suciu, S, Eggermont, AMM, Lorigan, P, Kirkwood, J, Markovic, S, Garbe, C, Cameron, D, Kotapati, S, Konto, C, Chen, T, Wheatley, K, Ives, N, De Schaetzen, G, Efendi, A & Buyse, M 2017, '1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS', Annals of Oncology, vol. 25, no. suppl_4, pp. iv376-iv376. https://doi.org/10.1093/annonc/mdu344.5

1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS. / Suciu, S.; Eggermont, A.M.M.; Lorigan, P. et al.
In: Annals of Oncology, Vol. 25, No. suppl_4, 03.02.2017, p. iv376-iv376.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - 1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS

AU - Suciu, S.

AU - Eggermont, A.M.M.

AU - Lorigan, P.

AU - Kirkwood, J.

AU - Markovic, S.

AU - Garbe, C.

AU - Cameron, D.

AU - Kotapati, S.

AU - Konto, C.

AU - Chen, T.

AU - Wheatley, K.

AU - Ives, N.

AU - De Schaetzen, G.

AU - Efendi, A.

AU - Buyse, M.

PY - 2017/2/3

Y1 - 2017/2/3

UR - http://www.mendeley.com/research/1089pdrelapsefree-survival-rfs-surrogate-endpoint-overall-survival-os-adjuvant-interferon-trials-pat

U2 - 10.1093/annonc/mdu344.5

DO - 10.1093/annonc/mdu344.5

M3 - Meeting Abstract

SN - 0923-7534

VL - 25

SP - iv376-iv376

JO - Annals of Oncology

JF - Annals of Oncology

IS - suppl_4

ER -

Suciu S, Eggermont AMM, Lorigan P, Kirkwood J, Markovic S, Garbe C et al. 1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS. Annals of Oncology. 2017 Feb 3;25(suppl_4):iv376-iv376. doi: 10.1093/annonc/mdu344.5

1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Cite this